DMAC
DiaMedica Therapeutics Inc. NASDAQ Listed Aug 3, 2012$5.85
+2.09%
vs $5.73
Mkt Cap $274.8M
52w Low $3.57
39.2% of range
52w High $9.39
50d MA $6.06
200d MA $7.16
P/E (TTM)
—
EV/EBITDA
—
P/B
4.9x
Debt/Equity
0.0x
ROE
-58.4%
P/FCF
-9.4x
RSI (14)
45.60
ATR (14)
$0.34
Beta
1.15
50d MA
$6.06
200d MA
$7.16
Avg Volume
173.7K
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Two Carlson Parkway · Minneapolis, MN 55447 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.17 | -0.19 | -11.8% | 6.52 | -1.2% | +0.2% | -3.2% | +2.1% | -2.0% | -0.9% | — |
| Mar 30, 2026 | AMC | -0.17 | -0.17 | +0.0% | 6.64 | +7.5% | +2.0% | -5.2% | +0.9% | +2.2% | -1.1% | — |
| Nov 12, 2025 | AMC | -0.15 | -0.17 | -13.3% | 6.31 | -6.3% | -14.1% | +9.4% | +8.1% | +7.6% | +5.8% | — |
| Aug 12, 2025 | AMC | -0.18 | -0.18 | +0.0% | 5.22 | -6.1% | +14.9% | +0.2% | +0.3% | -4.5% | +0.2% | — |
| May 13, 2025 | AMC | -0.18 | -0.18 | +0.0% | 3.98 | -1.8% | +0.5% | +1.8% | +3.2% | +1.7% | -3.0% | — |
| Mar 17, 2025 | AMC | -0.17 | -0.18 | -5.9% | 5.99 | +0.2% | -13.0% | +0.6% | -1.9% | -3.1% | -0.6% | — |
| Nov 13, 2024 | AMC | -0.15 | -0.15 | +0.0% | 4.26 | +0.7% | -3.3% | -2.7% | +3.5% | -2.7% | -0.5% | — |
| Aug 7, 2024 | AMC | -0.16 | -0.13 | +18.8% | 3.25 | +0.9% | +3.1% | +6.0% | -0.6% | +1.4% | -2.8% | — |
| May 8, 2024 | AMC | -0.16 | -0.14 | +12.5% | 3.47 | -2.9% | -6.3% | -4.0% | +2.2% | -5.3% | -0.3% | — |
| Mar 19, 2024 | AMC | -0.14 | -0.14 | +0.0% | 2.82 | +1.4% | -1.8% | -2.9% | +2.2% | -2.5% | +1.5% | — |
| Nov 13, 2023 | AMC | -0.14 | -0.12 | +14.3% | 2.34 | -9.4% | +6.8% | -2.0% | -2.9% | +4.6% | -2.8% | — |
| Aug 14, 2023 | AMC | -0.22 | -0.16 | +27.3% | 2.84 | -4.2% | +4.6% | +3.7% | -7.8% | +1.1% | +1.7% | — |
| May 15, 2023 | AMC | -0.16 | -0.20 | -25.0% | 1.99 | +1.0% | -11.1% | -1.1% | +20.6% | +6.6% | +24.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.01 | $6.02 | +0.2% | +0.3% | -4.5% | +0.2% | +4.0% | -1.2% |
| Jul 18 | Craig-Hallum | Maintains | Buy → Buy | — | $3.93 | $4.04 | +2.8% | +6.4% | +8.6% | +1.3% | +12.0% | -5.2% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.93 | $4.04 | +2.8% | +6.4% | +8.6% | +1.3% | +12.0% | -5.2% |
| Jul 18 | Lake Street | Maintains | Buy → Buy | — | $3.93 | $4.04 | +2.8% | +6.4% | +8.6% | +1.3% | +12.0% | -5.2% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.16 | $4.24 | +1.9% | +0.7% | -1.9% | +1.5% | -1.2% | +1.9% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.21 | $5.25 | +0.8% | +0.6% | -1.9% | -3.1% | -0.6% | -7.7% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.12 | $4.16 | +1.0% | -2.7% | +3.5% | -2.7% | -0.5% | +4.0% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.50 | +0.0% | -1.8% | -3.8% | +4.9% | -0.2% | -1.1% |
| Aug 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.51 | $3.46 | -1.4% | +2.6% | -0.8% | +3.6% | +0.0% | +7.6% |
| Mar 21 | Craig-Hallum | Maintains | Buy → Buy | — | $2.77 | $2.80 | +1.1% | -2.9% | +2.2% | -2.5% | +1.5% | -2.6% |
| Mar 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.77 | $2.80 | +1.1% | -2.9% | +2.2% | -2.5% | +1.5% | -2.6% |
| Jun 22 | Oppenheimer | Upgrade | Perform → Outperform | — | $3.64 | $3.85 | +5.8% | +11.3% | +4.9% | +3.5% | -3.4% | -0.7% |
| Jul 7 | Craig-Hallum | Maintains | Buy → Buy | — | $2.02 | $1.27 | -37.1% | -37.6% | +7.1% | -3.7% | -1.5% | +4.7% |
| Jul 7 | Oppenheimer | Downgrade | Outperform → Perform | — | $2.02 | $1.27 | -37.1% | -37.6% | +7.1% | -3.7% | -1.5% | +4.7% |
| Jul 7 | Lake Street | Maintains | Buy → Buy | — | $2.02 | $1.27 | -37.1% | -37.6% | +7.1% | -3.7% | -1.5% | +4.7% |
| Jun 30 | Roth Capital | Maintains | Buy → Buy | — | $4.74 | $4.66 | -1.7% | -6.1% | -3.6% | -1.6% | -6.9% | +7.1% |
| Apr 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.40 | $9.65 | +2.7% | +5.4% | -5.7% | -1.4% | +3.5% | +3.1% |
| Apr 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.35 | $9.45 | +1.1% | +0.5% | +5.4% | -5.7% | -1.4% | +3.5% |
| Feb 17 | Roth Capital | Maintains | Buy → Buy | — | $9.40 | $10.54 | +12.1% | +10.9% | -2.6% | +2.8% | -5.1% | -4.6% |
| Jul 8 | Maxim Group | Maintains | Buy → Buy | — | $6.75 | $7.28 | +7.9% | +2.5% | -3.2% | -8.2% | -5.7% | +1.7% |
| May 15 | Craig-Hallum | Maintains | Buy → Buy | — | $4.50 | $4.69 | +4.2% | +0.0% | +9.1% | -6.9% | +8.3% | -5.9% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Cooperman Leon G | 2,020,000 | $14M | — | Mar 2026 |
| 2 | Morgan Stanley | 1,095,220 | $9M | Reduced | Dec 2025 |
| 3 | Millennium Management | 935,592 | $6M | Added | Mar 2026 |
| 4 | Northern Trust Corp | 338,526 | $2M | Added | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 333,456 | $2M | New | Mar 2026 |
| 6 | Vanguard Portfolio Management Llc | 203,459 | $1M | New | Mar 2026 |
| 7 | Citadel Advisors Llc | 145,724 | $987K | Added | Mar 2026 |
| 8 | Sei Investments Co | 111,320 | $754K | Added | Mar 2026 |
| 9 | Bank Of New York Mellon Corp | 111,079 | $752K | Reduced | Mar 2026 |
| 10 | Members Wealth Llc | 101,382 | $656K | — | Mar 2026 |
| 11 | Informed Momentum Co Llc | 91,425 | $619K | — | Mar 2026 |
| 12 | Blue Trust, Inc. | 69,122 | $550K | — | Dec 2025 |
| 13 | Nuveen, Llc | 79,110 | $536K | Reduced | Mar 2026 |
| 14 | Kalehua Capital Management Llc | 62,488 | $423K | Reduced | Mar 2026 |
| 15 | Corient Ia Llc | 60,000 | $406K | New | Mar 2026 |
| 16 | Renaissance Technologies Llc | 52,523 | $356K | New | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 42,768 | $290K | Added | Mar 2026 |
| 18 | Catalyst Financial Partners Llc | 38,457 | $260K | — | Mar 2026 |
| 19 | Invesco Ltd. | 24,799 | $168K | Added | Mar 2026 |
| 20 | Royal Bank Of Canada | 23,343 | $157K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$274.8M
Enterprise Value
$214.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.68x
P/B
4.90x
P/S
—
P/FCF
-9.44x
EV/EBITDA
—
Shares Out
47.0M
Financials (TTM)
Revenue
$0
Net Income
-$35.1M
EBITDA
-$35.0M
Free Cash Flow
-$29.1M
Op Cash Flow
-$29.1M
EPS Basic
$-0.70
EPS Diluted
$-0.71
EPS Forward
$-0.76
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$61.4M
Total Liab.
$5.3M
Total Equity
$56.1M
Cash
$59.9M
LT Debt
$0
Book Value/Sh
$1.19
Debt/Equity
0.00x
Current Ratio
11.81
Quick Ratio
11.81
Returns & Growth
ROE
-58.4%
ROA
-53.4%
ROIC
-61.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-16.7%
Price Returns
2W
-5.8%
1M
-1.0%
3M
-24.7%
6M
-30.6%
12M
+45.7%
Technicals
52W High
$9.39
52W Low
$3.57
50d MA
$6.06
200d MA
$7.16
RSI (14)
45.60
ATR (14)
$0.34
Beta
1.15
Avg Volume
174K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.33
High
$10.00
Low
$7.00
Median
$8.00
Data updated apr 25, 2026 5:26am
· Source: financialmodelingprep.com